For cannabis operators, investors, medical patients, advocates, and regulators, the June 29 marijuana rescheduling hearing represents another major step in the ongoing debate surrounding marijuana’s place within the Controlled Substances Act.
While cannabis remains federally illegal in many respects, recent federal actions have fueled renewed optimism that meaningful reform may finally be gaining momentum.
The cannabis industry is preparing for what could become one of the most important federal policy discussions of 2026 as the U.S. Drug Enforcement Administration prepares to hold a hearing on June 29 regarding the future classification of marijuana under federal law.
The upcoming proceeding follows months of legal challenges, administrative reviews, and policy changes that have brought cannabis rescheduling back into the national spotlight. Although the hearing itself will not immediately legalize marijuana or transform the industry overnight, the outcome could influence taxation, research opportunities, regulatory frameworks, and future business growth throughout the United States.
Why Federal Marijuana Rescheduling Is So Important
For decades, marijuana has been classified as a Schedule I controlled substance under federal law. Schedule I is the most restrictive category under the Controlled Substances Act and has historically been reserved for substances that federal authorities considered to have a high potential for abuse and no accepted medical use.
That classification has long created tension between federal law and state-level cannabis programs.
Today, dozens of states have legalized medical cannabis, while a growing number have adopted adult-use recreational markets. Legal cannabis sales generate billions of dollars annually and support hundreds of thousands of jobs across cultivation, manufacturing, retail, distribution, testing, technology, and ancillary services.
Despite that growth, federal prohibition continues to create significant obstacles for businesses.
Cannabis companies often face limited banking access, higher borrowing costs, restrictions on interstate commerce, and one of the industry’s most significant burdens: Internal Revenue Code Section 280E.
Under 280E, cannabis businesses are prohibited from taking many of the standard business deductions available to other industries because marijuana remains federally classified as a Schedule I substance.
For many operators, rescheduling represents more than symbolic reform. It could directly impact profitability and long-term sustainability.
What Happened Earlier This Year
Federal cannabis policy took a significant turn earlier this year when the Department of Justice and DEA finalized actions affecting certain marijuana-related products.
The federal government moved FDA-approved cannabis products and marijuana operating under qualifying state medical programs into Schedule III, marking one of the most substantial federal cannabis policy developments in decades. While the change did not broadly legalize marijuana, it signaled a willingness among federal regulators to reconsider longstanding positions regarding cannabis and medical use.
The move immediately sparked debate throughout the industry.
Supporters viewed the decision as evidence that broader reform could eventually follow. Critics argued that the changes were limited in scope and left many of the industry’s biggest challenges unresolved.
Nonetheless, the action established the framework for the June 29 hearing and placed federal marijuana policy back at the center of national conversation.
What Will Happen On June 29?
According to notices published by federal regulators, the hearing scheduled for June 29 will examine whether marijuana should be more broadly transferred from Schedule I to Schedule III. The administrative proceeding will allow regulators, industry participants, researchers, medical professionals, legal experts, and other stakeholders to present evidence and testimony regarding marijuana’s classification.
The marijuana rescheduling hearing is expected to focus on several key areas:
- Medical evidence supporting cannabis use
- Public health considerations
- Regulatory implications
- Economic impacts
- Scientific research opportunities
- Federal enforcement concerns
- State cannabis market realities
While administrative hearings can sometimes move slowly, many industry observers believe this proceeding could play a meaningful role in shaping future federal cannabis policy.
The hearing will not produce an immediate final decision, but it could significantly influence the DEA’s ongoing evaluation process.
Potential Benefits For Cannabis Businesses
One of the primary reasons cannabis operators are paying close attention to the hearing involves taxation. Many cannabis companies have struggled financially despite strong consumer demand because of 280E tax restrictions. Rescheduling marijuana to Schedule III could potentially remove those limitations and allow operators to deduct ordinary business expenses in a manner similar to other legal industries.
For some companies, the resulting tax savings could be substantial.
Industry analysts have estimated that eliminating 280E restrictions could dramatically improve cash flow, increase profitability, and create opportunities for reinvestment into operations, staffing, product development, and expansion.
Beyond taxes, broader Schedule III classification could also help:
- Expand cannabis research opportunities
- Improve relationships with financial institutions
- Encourage institutional investment
- Increase participation from healthcare providers
- Strengthen legitimacy within regulated markets
- Reduce certain compliance barriers
While rescheduling would not create a federally legal adult-use market, many operators view it as an important step toward broader reform.
Questions That Still Need Answers About Marijuana Rescheduling
Despite growing optimism, significant uncertainty remains. One of the largest questions involves how federal regulators would handle the distinction between medical and adult-use cannabis markets.
Many state programs include both medical and recreational sales. If broader Schedule III classification occurs, regulators may face challenges determining how different segments of the industry should be treated under federal law.
Banking reform also remains unresolved.
Although marijuana rescheduling could improve relationships between cannabis companies and financial institutions, it would not automatically eliminate every barrier to traditional banking services. Additional congressional action may still be necessary to fully address those challenges.
Interstate commerce is another major issue.
Even if marijuana moves to Schedule III, individual state regulations and federal restrictions could continue limiting the movement of cannabis products across state lines.
For operators hoping for immediate nationwide legalization, the hearing is unlikely to provide that outcome.
Instead, it should be viewed as another step in a longer federal reform process.
Investors Are Watching Closely
Cannabis investors have experienced years of volatility driven largely by regulatory uncertainty.
Federal reform discussions have repeatedly generated market enthusiasm, only to be followed by delays, political disagreements, lawsuits, and regulatory complications.
As a result, many investors are approaching the June 29 hearing with cautious optimism.
Publicly traded cannabis companies, ancillary service providers, and multi-state operators could all be affected by any future rescheduling decisions.
Even incremental progress toward federal reform has historically influenced cannabis stock performance and investor sentiment.
The hearing’s outcome may provide important clues regarding how aggressively federal regulators intend to pursue future cannabis policy changes.
A Defining Moment For Federal Cannabis Reform
The cannabis industry has spent years navigating the gap between state legalization and federal prohibition. While the June 29 DEA hearing will not immediately solve every challenge facing operators, it represents one of the most significant federal cannabis events of 2026.
Questions surrounding taxation, research, banking, healthcare integration, and regulatory consistency all remain on the table.
For cannabis businesses, the stakes are substantial. With investors, the hearing could offer insight into the future direction of federal marijuana policy.
And for consumers, patients, and advocates, June 29 may become another important milestone in the ongoing evolution of cannabis reform in the United States.
As federal regulators gather testimony and review evidence, the cannabis industry will be watching closely to see whether broader Schedule III marijuana rescheduling finally moves one step closer to becoming reality.
–
For more updates on marijuana rescheduling and other weed news, subscribe to RespectMyRegion.com‘s newsletter.
Sources: Federal Register, U.S. Department of Justice, Drug Enforcement Administration, Reuters.
Editorial Disclaimer: This article is for informational and educational purposes only and should not be considered legal, financial, tax, or investment advice. Cannabis laws and regulations continue to evolve at the federal, state, and local levels. Readers should consult qualified legal, tax, or compliance professionals regarding specific business or regulatory questions.
